Original Research
Extended stability of the trastuzumab biosimilar ABP 980 (KANJINTI®) in polyolefin bags and elastomeric devices
Author byline as per print journal: Lyndsay Davies1, PhD; Katie Milligan1, BSc; Mark Corris1, BSc; Ian Clarke1; Paul Dwyer1, MSc; Sarah Elizabeth Lee2, PhD; Jolene Teraoka3, BSc; Jill Crouse-Zeineddini3, PhD;… Read More »
European prescribers’ attitudes and beliefs on biologicals prescribing and automatic substitution
Published in: Volume 9 / Year 2020 / Issue 3
Author(s): Madelaine A Feldman, MD, FACR, Michael S Reilly, Esq
Page: 116-24
Author(s): Madelaine A Feldman, MD, FACR, Michael S Reilly, Esq
Page: 116-24
Introduction: The European Union (EU) and the European Medicines Agency (EMA) have led the development of a regulatory framework for biosimilars since 2004. By end of December 2019, 64 biosimilars… Read More »
The European framework for intellectual property rights for biological medicines
Author byline as per print journal: Josette Sciberras, MBA, MA Bioethics, BPharm (Hons); Raymond Zammit, SThD; Patricia Vella Bonanno, PhD Introduction: The Pharmaceutical Strategy for Europe (2020) proposes actions related… Read More »